Compare Invitation Homes Inc. Common Stock (INVH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invitation Homes Inc. Common Stock vs Sana Biotechnology Inc — how do they compare? Invitation Homes Inc. Common Stock trades at $26.54 (market cap $15.70B), while Sana Biotechnology Inc trades at $2.34 (market cap $719.96M). The key difference: Invitation Homes Inc. Common Stock is far larger — about 21.8× Sana Biotechnology Inc's market cap, and Invitation Homes Inc. Common Stock pays a 4.51% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and Sana Biotechnology Inc for 24 Days on average.
| INVH | SANA | |
|---|---|---|
Market Cap | $15.70B | $719.96M |
Volume | 4,685,416 | 4,901,517 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $5.92 |
52-Week Low | $24.39 | $2.33 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $24.16B | $633.21M |
Dividend Yield | 4.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
